Program
Anti-TF/TOP1i Antibody-drug Conjugate XNW28012
Also written as “XNW28012” and “XNW28012 for injection”.
Its studies are mostly in Pancreatic Neoplasms, led by Evopoint Biosciences.
Drug pageAnti-TF/TOP1i Antibody-drug Conjugate XNW28012: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Jul 21, 20263 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Evopoint Biosciences | 33 open or running | phase 3since Jul 21, 2026 | Dec 25, 2024 | Dec 31, 2026phase 2 · NCT06799637 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 25, 2024First study: phase 2 study in Pancreatic NeoplasmsFirst studyNCT06799637 · 350 planned · China
- Jul 6, 2026Phase 1 study in Pancreatic NeoplasmsNCT07707674 · 24 planned · United States
- Jul 21, 2026Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07823049 · 226 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06799637
- May 31, 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07823049
- Apr 30, 2028Primary completion: phase 1 study in Pancreatic NeoplasmsNCT07707674
TargetBeta
F3 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody against human tissue factor (TF; F3; coagulation factor III; thromboplastin; CD142) ”NCIt, by rule
Other programs on F3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tisotumab vedotinrule | Pfizer | phase 4 | 11 |
| Anti-TF Antibody-drug Conjugate MRG004Arule | lepu-biopharma-co-ltd | phase 3 | 2 |
| SHR-4375 | Jiangsu HengRui Medicine | phase 2 | 2 |
| Anti-TF/TOP1i Antibody-drug Conjugate XB371rule | Exelixis | phase 1 | 1 |
| Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rule | sutro-biopharma-inc | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07823049Pancreatic Neoplasms · China | 3 | Recruiting | May 31, 2027 | 226 |
| NCT07707674Pancreatic Neoplasms · United States | 1 | Not yet recruiting | Apr 30, 2028 | 24 |
| NCT06799637Pancreatic Neoplasms · China | 2 | Recruiting | Dec 31, 2026 | 350 |
How it is read
Names in the registry
- “XNW28012”, 2 entries
- “XNW28012 for injection”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.